Patents by Inventor Dean Falb

Dean Falb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL
    Publication number: 20180325963
    Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
    Type: Application
    Filed: August 31, 2016
    Publication date: November 15, 2018
    Applicant: Synlogic, Inc.
    Inventors: Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
  • BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA
    Publication number: 20180320161
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: November 16, 2016
    Publication date: November 8, 2018
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tightened Gut Mucosal Barrier
    Publication number: 20180312851
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: September 8, 2016
    Publication date: November 1, 2018
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER
    Publication number: 20180280451
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Application
    Filed: December 22, 2017
    Publication date: October 4, 2018
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
    Publication number: 20180273956
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: January 11, 2018
    Publication date: September 27, 2018
    Applicant: Synlogic, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
  • BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER
    Publication number: 20180169154
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Application
    Filed: December 22, 2017
    Publication date: June 21, 2018
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 9943555
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: April 17, 2018
    Assignee: Synlogic, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Sarah Rowe
  • Bacteria engineered to treat a disease or disorder
    Patent number: 9889164
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 13, 2018
    Assignee: Synlogic, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • PROBIOTIC ORGANISMS FOR DIAGNOSIS, MONITORING, AND TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Publication number: 20170360850
    Abstract: Aspects of the present disclosure relate to genetically engineered organisms useful for the diagnosis and treatment of inflammatory bowel disease.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 21, 2017
    Applicants: Massachusetts Institute of Technology, Synlogic, Inc.
    Inventors: Timothy Kuan-Ta Lu, Jacob Rosenblum Rubens, Isaak Elis Mueller, Gianluca Selvaggio, Paul Miller, Dean Falb, Vincent Isabella, Jonathan Kotula
  • BACTERIA ENGINEERED TO REDUCE HYPERPHENYLALANINEMIA
    Publication number: 20170312320
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: May 13, 2016
    Publication date: November 2, 2017
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • Bacteria Engineered to Treat Diseases Associated with Hyperammonemia
    Publication number: 20170253862
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 7, 2017
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID
    Publication number: 20170232043
    Abstract: The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a branched chain amino acid catabolism enzyme. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of branched chain amino acids using the pharmaceutical compositions disclosed herein.
    Type: Application
    Filed: December 14, 2016
    Publication date: August 17, 2017
    Inventors: Dean Falb, Paul F. Miller, Yves Millet, Vincent M. Isabella, Jonathan W. Kotula, Alex Tucker
  • BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING PROPIONATE CATABOLISM
    Publication number: 20170216370
    Abstract: The present disclosure provides engineered bacterial cells comprising a heterologous gene encoding a propionate catabolism enzyme. In another aspect, the engineered bacterial cells further comprise at least one heterologous gene encoding a transporter of propionate or a kill switch. The disclosure further provides pharmaceutical compositions comprising the engineered bacteria, and methods for treating disorders involving the catabolism of propionate, such as Propionic Acidemia and Methylmalonic Acidemia, using the pharmaceutical compositions.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 3, 2017
    Inventors: Dean Falb, Paul F. Miller, Alex Tucker, Jonathan W. Kotula, Vincent M. Isabella, Yves Millet
  • Bacteria engineered to treat diseases associated with hyperammonemia
    Patent number: 9688967
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: June 27, 2017
    Assignee: Synlogic, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • Bacteria Engineered to Treat Diseases Associated with Hyperammonemia
    Publication number: 20170137789
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Application
    Filed: May 25, 2016
    Publication date: May 18, 2017
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER
    Publication number: 20170136073
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Application
    Filed: May 13, 2016
    Publication date: May 18, 2017
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
    Publication number: 20170128499
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: March 2, 2016
    Publication date: May 11, 2017
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
  • BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
    Publication number: 20170067065
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: September 8, 2016
    Publication date: March 9, 2017
    Applicant: Synlogic, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Bacteria Engineered to Reduce Hyperphenylalaninemia
    Publication number: 20170014457
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: September 8, 2016
    Publication date: January 19, 2017
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves MILLET, Sarah ROWE
  • Bacteria Engineered to Reduce Hyperphenylalaninemia
    Publication number: 20160340665
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Application
    Filed: May 13, 2016
    Publication date: November 24, 2016
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller